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Abstract In the last few years, many efforts have been
made to search for potent and selective human A3
adenosine antagonists. In particular, one of the most
promising human A3 adenosine receptor antagonists is
represented by the pyrazolo-triazolo-pyrimidine family.
This class of compounds has been strongly investigated
from the point of view of structure-activity relationships. In
particular, it has been observed that fundamental requisites
for having both potency and selectivity at the human A3
adenosine receptors are the presence of a small substituent
at the N
8 position and an unsubstitued phenyl carbamoyl
moiety at the N
5 position. In this study, we report the role
of the N
5-bond type on the affinity and selectivity at the
four adenosine receptor subtypes. The observed structure-
activity relationships of this class of antagonists are also
exhaustively rationalized using the recently published
ligand-based homology modeling approach.
Keywords Adenosinereceptors.Antagonistbinding.
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Abbreviations
CHO cells chinese hamster ovary cells
EtOAc ethyl acetate
TLC thin layer chromatography
NMR nuclear magnetic resonance
IR infrared spectra
CDC13 deuterated chloroform
Na2SO4 sodium sulphate
mp melting point
KBr potassium bromide
DMSO-d6 deuterated dimethylsulfoxide
CCPA 2-Chloro-N
6-cyclopentyladenosine
NECA 5′-(N-Ethylcarbamoyl)adenosine
R-PIA R(-)-N
6-Cyclopentyladenosine
Introduction
Adenosine is an ubiquitous modulator, which exerts its
functions through interaction with four G-protein-coupled
receptors classified as A1,A 2A,A 2B and A3 [1]. In recent
decades, intensive and successful efforts have been made
by medicinal chemists to discover potent and selective
ligands (both agonists and antagonists) for almost all
adenosine receptor subtypes [2, 3]. Only the A2B subtype
is still without a very potent and selective agonist ligand
[4–6]. At the same time, great progress has been made in
the field of human A3 adenosine receptor antagonists. This
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(*)receptor seems to be associated with cerebroprotection [7,
8] and cardioprotection [9] and effects on the immune and
inflammatory systems [10, 11]. The A3 adenosine receptor
subtype, recently cloned from different species (e.g., rat,
human, dog, sheep) [12, 13], is coupled to the modulation
of at least two second-messenger systems: inhibition of
adenylate cyclase and stimulation of phospholipase C and
D[ 12, 13]. In humans, A3 receptors have been found in
several organs, such as lung, liver, kidney, heart, and with a
lower density, in the brain [9, 12, 13]. This receptor subtype
is under examination in relation to its potential therapeutic
applications. In particular, antagonists for A3 receptors
seem to be useful for the treatment of inflammation or
glaucoma [14, 15].
In the last 5 years, many efforts have been made in the
context of searching for potent and selective human A3
adenosine antagonists. In this field, several different classes
of compounds have been proposed, possessing good affinity
(nM range) and with a broad range of selectivity [16].
In particular one of the most attractive human A3
adenosine receptor antagonists is represented by the
pyrazolo-triazolo-pyrimidine family, reported by our group
[17–23]. In Fig. 1, the most interesting members of this
class of compounds (1–3), which display high affinity and
selectivity for this receptor subtype, are depicted [17–23].
This class of compounds has been strongly investigated
from the point of view of structure-activity relationships. In
particular, it has been observed that fundamental requisites
for having both potency and selectivity at the human A3
adenosine receptors are a small substituent at the N
8
position and an unsubstituted phenyl carbamoyl moiety at
the N
5 position [17, 21]. In contrast, when the phenyl
carbamoyl moiety (2) was replaced with a phenylacetyl
group (3), a significant decrease in affinity at the hA3
adenosine receptors with a simultaneous retention or a
slight increase in affinity at the hA2B adenosine receptor
subtype was observed [24].
These data seem to suggest that bond type at the N
5
position plays a fundamental role in the receptor recognition.
For this reason, we decided to further investigate the effect
of the bond nature at this position on affinity and selectivity,
synthesizing two new derivatives bearing the benzoyl- (4)
and benzensulfonamido (5)m o i e t i e sa tt h eN
5 position.
Chemistry
The designed compounds (4, 5) were easily prepared by
treating the well-known N
8 methyl derivative (6)[ 18] with
benzoyl (7) or benzensulfonyl (8) chlorides in dioxane in
the presence of pyridine at reflux for 16 h (Scheme 1).
Results and discussion
Newly synthesized (4, 5) and reference compounds (2, 3)
were tested at the human A1,A 2A and A3 receptors
expressed in CHO cells; [
3H]CCPA (A1) and [
3H]NECA
(A2A,A 3) were used as radioligands in binding assays [25].
Radioligand binding at A2B adenosine receptors is prob-
lematic as no high-affinity ligand is readily available for
this subtype. Therefore, inhibition of NECA-stimulated
adenylyl cyclase activity was determined as a measurement
of affinity of compounds (Table 1).
A careful examination of the data clearly revealed
significant differences in the binding profile of the
reference compounds (2, 3) compared with the literature
data (see Fig. 1). In fact, in these binding studies,
compound 2 was found to be ninefold less potent at the
hA3 receptors with a consequent reduction in selectivity
versus the other receptor subtypes, in particular versus
hA2A (hA2A/hA3=15). In contrast, derivative 3 retained
good affinity at the hA3 adenosine receptor and a quite
good range of selectivity versus the other receptors in
comparison with literature data. Also if these discrepancies
in binding profile could be attributed to a different
biological method utilized (e.g., radioligand), the data seem
to indicate that the phenylacetyl moiety retains or enhances
both potency and selectivity compared with the well-known
phenylcarbamoyl chain. A significantly different binding
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Fig. 1 Structures and binding
profiles of some representative
pyrazolo-triazolo-pyrimidines as
human A3 adenosine receptor
antagonists
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5
position was alternatively modified. Introduction of a
shorter amide (4) with respect phenylacetyl chain (3) led
to a loss of potency at all four adenosine receptor subtypes,
but a quite good retention of selectivity was observed. In
contrast, the presence of a benzensulfonamido moiety at the
N
5 position induced a substantial loss of both potency and
selectivity at the four adenosine receptor subtypes.
Molecular modeling studies were performed on the
pyrazolo-triazolo-pyrimidine derivatives 2–5 in order to
identify the hypothetical binding motif of these N
5 analogues
and to rationalize their structure-activity relationship.
Following our previously reported modeling studies [17–
23], we built up a refined model of human A3 receptor by
using a rhodopsin-based homology modeling (RBHM)
approach [26–29]. Moreover, our recently described ligand-
based homology modeling methodology (LBHM) has been
used to simulate the conformational changes induced by
ligand binding (methodological details are summarized in the
Experimental Section)[ 29, 30].
Using this methodology, we found an “expanded”
conformational model of the human A3 receptor reverse
agonist-like state, in which both shape and chemical
complementarities have been specifically optimized around
each ligand. Considering these new N
5 analogues, the
molecular volume of transmembrane (TM) binding cavity
has been changed from 660 (A3 model obtained by the
conventional rhodopsin-based homology modeling) to 840
Å
3 (expanded A3 model obtained by ligand-based homol-
ogy modeling) without altering the conventional rhodopsin-
like receptor topology. The binding cavity reorganization
induced by ligand binding is due to the conformational
change in several amino acid side chains, such as Leu90
(3.32), Leu91 (3.33), Thr94 (3.36), His95 (3.37), Ile98
(3.40), Gln167 (EL2), Phe168 (EL2), Phe182 (5.43), Ile186
(5.47), Leu190 (5.51), Phe239 (6.44), Trp243 (6.48),
Leu244 (6.49), Leu264 (7.35), and Ile268 (7.39).
Interestingly, none of the new pyrazoloquinoline antag-
onists found an energetically stable docking pose in the
conventional RBHM-driven A3 model. This is mainly due
to the unfavorable topological complementarity among
these antagonists and corresponding RBHM-driven TM
binding cavity. In particular, highly destabilizing van der
Waals interactions (steric conflicts) seem to be the reason
for absent topological complementarities. These steric
conflicts are drastically reduced or completely eliminated
after the application of the LBHM approach.
Molecular docking studies were carried out for the
pyrazolo-triazolo-pyrimidine antagonists 2–4,u s i n gt h e
“expanded” conformational state of the receptor. As shown
in Fig. 2, we found a similar binding motif indicating that a
common receptor-driven pharmacophore model can be
depicted. This finding is in agreement with our previously
reported studies [17–23].
Indeed, ligand recognition occurs in the upper region of
the TM bundle, and the pyrazolo-triazolo-pyrimidine
Scheme 1 Preparation of
designed compounds
Table 1 Biological profile of synthesized (4, 5) and reference (2, 3) compounds
Compound R hA1
a (Ki nM) hA2A
b (Ki nM) hA2B
c (IC50 nM) hA3
d (Ki nM) hA1/hA3 hA2A/hA3
2 CONHPh 310 (295–327) 27.7 (13.3–57.8) 3,440 (2,880–4,110) 1.80 (0.88–3.68) 172 15
3 COCH2Ph 1,040 (864–1,260) 282 (201–375) 12,620 (9,730–16,400) 0.92 (0.80–1.06) 1,130 360
4 COPh 2,030 (1,710–2,400) 879 (643–1,200) >30,000 15.7 (7.85–31.5) 129 56
5 SO2Ph 20,700 (16,700–25,700) 6,060 (5,170–7,110) >30,000 744 (534–1,040) 28 8
Data are expressed as geometric means, with 95% confidence limits
aDisplacement of specific [
3H]-CCPA binding at human A1 receptors expressed in CHO cells, (n=3–6)
bDisplacement of specific [
3H]-NECA binding at human A2A receptors expressed in CHO cells
cIC50 values of the inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA2B receptors
dDisplacement of specific [
3H]-NECA binding at human A3 receptors expressed in CHO cells
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in the N
5 position oriented toward the intracellular
environment. As shown in Fig. 2, the furan ring at the 2-
position is close to TMs 3 and 7. Interestingly, an important
hydrogen bonding network can be observed in all energet-
ically stable docked conformations of pyrazolo-triazolo-
pyrimidine antagonists. In particular His95 (3.37) and
Ser247 (6.52) are able to interact through hydrogen
bonding with the N
5-carbonyl oxygen of compounds 2–4
(2C=O·His95 ca. 3.0 Å; 3C=O·Ser247 ca. 2.8 Å; 4C=O·His95
ca. 2.9 Å.)
These polar amino acids seem to be critical for the
recognition of all antagonist structures and for receptor
selectivity. In particular, Ser247 (6.52) of human A3
receptor subtype is not present in the corresponding
position of A1 and A2 receptors, where the residue is
replaced by a histidine (His251 in human A1, His250 in
human A2A and His251 in human A2B). Histidine side
chain is bulkier than serine, and possibly for this reason,
large substituents at the N
5 position of pyrazolo-triazolo-
pyrimidine framework are not well tolerated by A1 and A2
receptor subtypes. In contrast, the hydroxyl group of
Ser247 (6.52) of human A3 receptor is appropriately
positioned to form a hydrogen-bonding interaction with
the carbonyl oxygen of the N
5-amide/ureide group of
compounds 2–4. These observations support the importance
of an N
5-acyl/carbamoyl group in modulating receptor
selectivity. The hydrophobic environment of the five nonpolar
amino acids Ile98 (3.40), Ile186 (5.47), Leu190 (5.51),
Phe239 (6.44), and Leu244 (6.49) can comfortably accom-
modate the phenyl ring of all N
5-acyl/carbamoyl derivatives.
In contrast, the introduction of the N
5-sulfonamido
moiety, as present in derivative 5, drastically reduces the
affinity at the human A3 receptor. Interestingly, in this
specific case molecular docking is not able to find an
antagonist pose comparable to those described for the other
N
5-acyl/carbamoyl derivatives. As shown in Fig. 3, the
rigid tetrahedral configuration associated with the N
5-
sulfonamido moiety avoids the sampling of energetically
favorable antagonist poses in which the phenyl ring is
linked to the N
5 position in the hydrophobic pocket
delimited by Ile98 (3.40), Ile186 (5.47), Leu190 (5.51),
Phe239 (6.44), and Leu244 (6.49).
The most stable docking pose of 5 presents the N
5-
sulfonamido moiety close to TM3 and TM7, and the phenyl
ring linked to N
5 position is surrounded by a hydrophobic
pocket delimited by Leu90 (3.32) and Ile268 (7.39). This
antagonist pose is energetically less stable (ca. 15 kcal/mol)
with respect to those found for derivatives 2–4, due to the
absence of the stabilizing interactions among the polar
residues Thr94 (3.36), His95 (3.37), and Ser247 (6.52) and
the N
5-sulfonamido moiety. Structure superimposition of
compounds 4 and 5 is shown in Fig. 4.
This severe steric constriction might explain the drastic
reduction in affinity of derivative 5 at the human A3 receptor.
Conclusions
The present study has led to potent and selective human A3
adenosine receptor antagonists belonging to the class of the
pyrazolo-triazolo-pyrimidine. In this study, we clarified the
Fig. 2 Hypothetical binding motif of the newly synthesized pyrazolo-
triazolo-pyrimidine antagonists 2–4. The most energetically favorable
docked conformation of each derivative is viewed from the membrane
side facing TM helices 4 and 5. To clarify the TM cavity, the view of
TM4 was omitted. Side chains of some amino acids important for
ligand recognition are highlighted. Hydrogen atoms are not displayed
Fig. 3 Hypothetical binding motif of the newly synthesized N
5-
sulfonamido pyrazolo-triazolo-pyrimidine antagonist 5.T h em o s t
energetically favorable docked conformation of each derivative is
viewed from the membrane side facing TM helices 4 and 5. To clarify
the TM cavity, the view of TM4 was omitted. Hydrogen atoms are not
displayed
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5-bond type on the affinity and selectivity at
the four adenosine receptor subtypes. In particular, we
confirmed the critical function played by the N
5-acyl/
carbamoyl moiety in receptor recognition. The observed
structure-activity relationship was also rationalized by the
recently published ligand-based homology modeling ap-
proach, indicating that chemical and topological properties
of the different ligands might induce important conforma-
tional changes in the antagonist-driven binding site of the
human A3 adenosine receptor.
Experimental section
Chemistry
General Reactions were routinely monitored by thin-layer
chromatography (TLC) ion silica gel (precoated F254 Merck
plates) and products visualized with iodine or potassium
permanganate solution. Infrared spectra (IR) were measured
on a Perkin Elmer 257 instrument.
1HN M Rw a s
determined in CDCl3 or DMSO-d6 solutions with a Bruker
AC 200 spectrometer; peak positions are given in parts per
million (6) downfield from tetramethylsilane as internal
standard, and J values are given in Hz. Light petroleum
ether refers to the fractions boiling at 40–60°C. Melting
points were determined on a Buchi-Tottoli instrument and
are uncorrected. Chromatographies were performed using
Merck 60–200 mesh silica gel. All products reported
showed IR and
1H NMR spectra in agreement with the
assigned structures. Organic solutions were dried over
anhydrous magnesium sulphate. Elemental analyses were
performed by the microanalytical laboratory of Diparti-
mento di Chimica, University of Trieste.
General procedures for the preparation of 5-(benzoyl)
amino-8-methyl-2-(2-furyl)-pyrazolo[4,3 ]-1,2,4-triazolo
[1,5-c]pyrimidine (4) and 5-benzensulfonamido-8-
methyl-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]
pyrimidine (5)
Amino compound (6) (10 mmol) was dissolved in freshly
distilled dioxane (15 mL), and benzoylchloride or benze-
sulfonyl chloride (13 mmol) and pyridine (20 mmol) were
added. The mixture was refluxed under argon for 16 h.
Then the solvent was removed under reduced pressure and
the residue was dissolved in EtOAc (30 ml) and washed
twice with water (15 mL). The organic phase was dried on
Na2SO4 and concentrated under reduced pressure. The residue
was purified by flash chromatography (EtOAc-light petroleum
8:2) to afford the desired compounds (4, 5)a ss o l i d s .
5-(Benzoyl)amino-8-methyl-2-(2-furyl)-pyrazolo[4,3-e]-
1,2,4-triazolo[1,5-c]pyrimidine (4)
Yield 78%, pale yellow solid, mp (EtOAc-light petroleum)
240°C; IR (KBr): 3,425-2,965, 1,675, 1,645, 1,620, 1,545,
1,450 cm
−1; 1 H NMR (DMSO d6) δ: 4.42 (s, 3H); 6.65
(dd, 1H, J=2, J=4); 7.24 (d, 1H, J=4); 7.41–7.62 (m, 4H);
7.85–7.98 (m, 2H); 8.14 (s, 1H); 9.87 (bs, 1H). Anal. for
C18H13N7O2 (MW 359.34). Calculated: C 50.16; H 3.69; N
27.29. Found: C 50.01; H 3.61; N 27.35.
5-Benzensulfonamido-8-methyl-2-(2-furyl)-pyrazolo
[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (5)
Yield 62%, white solid, mp (EtOAc-light petroleum) >
300°C; IR (KBr): 3,375-2,985, 1,640, 1,600, 1,540, 1,355,
1,150 cm
−1; 1H NMR (DMSO d6) δ: 4.39 (s, 3H); 6.68 (dd,
1H, J=2, J=4); 7.22 (d, 1H, J=4); 7.38–7.59 (m, 4H); 7.88-
8.02 (m, 2H); 8.11 (s, 1H); 11.05 (bs, 1H). Anal. for
C17H13N7O3S (MW 395.40). Calculated: C 51.64; H 3.31;
N 24.80; S 8.11. Found: C 51.87; H 3.35; N 24.97; S 8.07.
Biology
All pharmacological methods followed the procedures as
described earlier [25]. In brief, membranes for radioligand
binding were prepared from CHO cells stably transfected
with human adenosine receptor subtypes in a two-step
Fig. 4 Structure superimposition of compounds 4 (in magenta) and 5
(in green) inside the receptor binding site
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fragments and nuclei were removed. The crude membrane
fraction was sedimented from the supernatant at 100,000×g.
The membrane pellet was resuspended in the buffer used for
the respective binding experiments, frozen in liquid nitrogen
and stored at −80°C. For the measurement of adenylyl
cyclase activity only one high-speed centrifugation of the
homogenate was used. The resulting crude membrane pellet
was resuspended in 50 mM Tris/HCl, pH 7.4 and immediately
used for the cyclase assay.
For radioligand binding at A1 adenosine receptors, 1 nM
[
3H]CCPA was used, whereas 30 and 10 nM [
3H]NECA
were used for A2A and A3 receptors, respectively. Nonspe-
cific binding of [
3H]CCPA was determined in the presence
of 1 mM theophylline, and in the case of [
3H]NECA,
100 pM R-PIA was used. Ki values from competition
experiments were calculated with the program SCTFIT [31].
Radioligand binding at A2B adenosine receptors is
problematic as no high-affinity ligand is available for this
subtype. Therefore, inhibition of NECA-stimulated
adenylyl cyclase activity was determined as a measurement
of affinity of compounds. IC50 values from these experi-
ments were converted to Ki values with the Cheng and
Prusoff equation [32].
Computational methodologies
All modeling studies were carried out on a 10 CPU (PIV-
3.0GHZ and AMD64) Linux cluster running under open-
Mosix architecture [33].
Homology modeling, energy calculation, and docking
studies were performed using the Molecular Operating
Environment (MOE, version 2006.08) suite [34].
All docked structures were fully optimized without
geometry constraints using RHF/AM1 semiempirical cal-
culations. Vibrational frequency analysis was used to
characterize the minima stationary points (zero imaginary
frequencies). The software package MOPAC (ver. 7) [35],
implemented in MOE suite, was utilized for all quantum
mechanical calculations.
Homology model of the human A3 AR B a s e do nt h e
assumption that GPCRs share similar TM boundaries and
overall topology, a homology model of the hA3 receptor
was constructed. First, the amino acid sequences of TM
helices of the A3 receptor were aligned with those of bovine
rhodopsin, guided by the highly conserved amino acid
residues, including the DRY motif (D3.49, R3.50, and
Y3.51) and three proline residues (P4.60, P6.50, and P7.50)
in the TM segments of GPCRs. The same boundaries were
applied for the TM helices of the A3 receptor as they were
identified from the X-ray crystal structure for the
corresponding sequences of bovine rhodopsin [36], the CR
coordinates of which were used to construct the seven TM
helices for the hA3 receptor.
The loop domains of the hA3 receptor were constructed
by the loop search method implemented in MOE. In
particular, loops are modeled first in random order. For
each loop, a contact energy function analyzes the list of
candidates collected in the segment searching stage, taking
into account all atoms already modeled and any atoms
specified by the user as belonging to the model environ-
ment. These energies are then used to make a Boltzmann-
weighted choice from the candidates, the coordinates of
which are then copied to the model. Any missing side-chain
atoms are modeled using the same procedure. Side chains
belonging to residues whose backbone coordinates were
copied from a template are modeled first, followed by side
chains of modeled loops. Outgaps and their side chains are
modeled last.
Special caution has to be given to the second extracel-
lular (EL2) loop, which has been described in bovine
rhodopsin as folding back over transmembrane helices [36]
and, therefore, limiting the size of the active site. Hence,
amino acids of this loop could be involved in direct
interactions with the ligands. A driving force for this
peculiar fold of the EL2 loop might be the presence of a
disulfide bridge between cysteines in TM3 and EL2. Since
this covalent link is conserved in all receptors modeled in
the current study, the EL2 loop was modeled using a
rhodopsin-like constrained geometry around the EL2-TM3
disulfide bridge. After the heavy atoms were modeled, all
hydrogen atoms were added, and the protein coordinates
were then minimized with MOE using the AMBER94 force
field [37]. The minimizations were carried out by the 1,000
steps of steepest descent followed by conjugate gradient
minimization until the rms gradient of the potential energy
was less than 0.1 kcal mol
−1 Å
−1. Protein stereochemistry
evaluation was performed by several tools (Ramachandran
and Chi plots measure phi/psi and chi1/chi2 angles, clash
contacts reports) implemented in MOE suite [34].
Ligand-based homology modeling We have recently revis-
ited the rhodopsin-based model of the human A3 receptor in
its resting state (antagonist-like state), taking into account a
novel strategy to simulate the possible receptor reorganiza-
tion induced by the antagonist-binding [28]. We called this
new strategy ligand-based homology modeling. Briefly,
ligand-based homology modeling technique is an evolution
of a conventional homology modeling algorithm based on a
Boltzmann-weighted randomized modeling procedure
adapted from Levitt [38] with specialized logic for the
proper handling of insertions and deletions so that any
selected atoms will be included in the energy tests and
minimization stages of the modeling procedure. Ligand-
44 Purinergic Signalling (2008) 4:39–46based option is very useful when one wishes to build a
homology model in the presence of a ligand docked to the
primary template, or other proteins known to be complexed
with the sequence to be modeled [34]. In this specific case,
both model building and refinement take into account the
presence of the ligand in terms of specific steric and
chemical features. In order to generate an initial ensemble
of ligand poses, a conventional docking procedure (see next
section for details) with reduced van der Waals radii (equal
to 75%) and an increased Coulomb-vdW cutoff (cutoff on
10 Å; cutoff on 12 Å) was performed. For each pose, an
homology model is then generated to accommodate the
ligand by reorienting nearby side chains. These residues
and the ligand are then locally minimized. Finally, each
ligand is re-docked into its corresponding low energy
protein structures and the resulting complexes are ranked
according to MOEScore [34].
Different quantitative measures of molecular volume of
the receptor binding cavities have been carried out by using
MOE suite [34]. Prediction of antagonist-receptor complex
stability (in terms of corresponding pKi value) and the
quantitative analysis for non-bonded intermolecular inter-
actions (H-bonds, transition metal, water bridges, hydro-
phobic) were calculated and visualized using several tools
implemented into MOE suite [34].
Molecular docking of the hA3 AR antagonists All antago-
nist structures were docked into the hypothetical TM
binding site by using the MOE-dock tool, part of the
MOE suite. Searching is conducted within a user-specified
3D docking box (the standard protocol selects all atoms
inside 12 Å from the center of mass of the binding cavity),
using the Tabu Search [39] protocol (standard parameters
are 1,000 steps/run, 10 attempts/step, and 10 Tabu list
length), and the MMFF94 force field [40]. MOE-dock
performs a user-specified number of independent docking
runs (50 in our specific case) and writes the resulting
conformations and their energies in a molecular database
file. The resulting docked complexes were subjected to
MMFF94 energy minimization until the rms of conjugate
gradient was <0.1 kcal mol
−1 Å
−1. Charges for the ligands
were imported from the MOPAC output files. To better
refine all antagonist-receptor complexes, a rotamer explo-
ration of all side chains involved in the antagonist-binding
was carried out. Rotamer exploration methodology was
implemented in MOE suite [34].
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